Proton pump inhibitor use and the efficacy and safety of immune checkpoint inhibitors in non-small cell lung cancer: a meta-analysis and FAERS pharmacovigilance study
This meta-analysis and FAERS pharmacovigilance study reveals that proton pump inhibitor use in non-small cell lung cancer patients receiving immune checkpoint inhibitors is significantly associated with reduced overall and progression-free survival without increasing overall adverse events, though it shifts the safety profile toward microbiota-related, infectious, and renal complications.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Lung cancer remains the most common cause of cancer death worldwide, with the majority of cases falling into a category known as non-small cell lung cancer. For decades, treatment relied heavily on chemotherapy, but a newer approach has fundamentally changed the landscape. This approach uses drugs called immune checkpoint inhibitors. These medicines do not attack the cancer directly; instead, they remove the biological "brakes" that cancer cells use to hide from the body's own immune system, allowing the patient's immune cells to recognize and destroy the tumor. While these drugs have saved lives, they do not work for everyone. Scientists have long suspected that the community of tiny organisms living in our gut, known as the gut microbiome, plays a crucial role in determining whether these treatments succeed. If the balance of these gut bacteria is disrupted, the immune system may fail to wake up and fight the cancer.
One of the most common medications prescribed to cancer patients is the proton pump inhibitor. These are drugs used to reduce stomach acid, often given to treat heartburn or to protect the stomach lining from other harsh treatments. Because they are so widely used, researchers have begun to wonder if these acid-suppressing drugs might accidentally harm the very immune response that the cancer treatment is trying to boost. The concern is that by changing the acidity of the stomach, these drugs could alter the environment of the gut, leading to a loss of beneficial bacteria and a shift toward a state that weakens the immune system's ability to respond to the cancer therapy.
A new study brings together a massive amount of evidence to answer this question specifically for patients with non-small cell lung cancer. The researchers combined a systematic review of forty-four different studies involving more than 58,000 patients with a separate, huge analysis of nearly 18 million real-world safety reports from the US Food and Drug Administration. By looking at this data, they sought to determine if taking proton pump inhibitors alongside immune checkpoint inhibitors changed the outcome of the cancer treatment or the safety profile of the drugs.
The findings were clear and consistent. Patients who were taking proton pump inhibitors when they started their immune therapy had significantly shorter survival times compared to those who were not taking these acid-reducing drugs. The data showed that the risk of death was higher for those on the acid-suppressing medication, and the time before the cancer began to grow again was also shorter. This negative effect was not limited to a specific type of immune drug or a specific treatment plan; it appeared across the board. However, the timing of the medication mattered greatly. The negative impact was strongest when the acid-suppressing drugs were taken in the weeks immediately surrounding the start of the immune therapy. This suggests that the state of the gut bacteria at the very beginning of treatment is critical for the immune system to mount a successful attack.
The study also revealed that this effect was not the same for everyone. The association between taking these acid drugs and poorer outcomes was significantly stronger in studies conducted in Asia compared to those in other parts of the world. The researchers noted that genetic differences in how people in Asian populations process these drugs could lead to higher levels of the medication in the blood, potentially causing a greater disruption to the gut environment. Despite the negative impact on how well the treatment worked, the study found that taking these drugs did not increase the overall number of severe side effects or the risk of death from the treatment itself. The drugs did not make the therapy more toxic in a general sense.
However, the safety analysis did uncover a shift in the types of problems that occurred. When patients took both the immune therapy and the acid-reducing drugs, the pattern of side effects changed. The data pointed to a higher likelihood of specific issues related to the gut, infections, and kidney function. For instance, there was a notable increase in reports of kidney inflammation and infections that are often linked to an imbalance in the body's microbial communities. This suggests that while the drugs might not make the treatment more dangerous overall, they do alter the body's response in ways that require careful monitoring, particularly regarding kidney health and infection risk.
The researchers concluded that the use of proton pump inhibitors in patients receiving immune therapy for lung cancer warrants a very careful review. The evidence suggests that if a patient does not have a strong medical reason to take these acid-reducing drugs, they should avoid them, especially during the critical window when the immune therapy is first starting. If a patient must take them, the goal should be to use the lowest effective dose for the shortest time necessary. The study does not call for a total ban on these medications, but it does highlight that their use is not neutral. By disturbing the gut environment, these common drugs may be quietly undermining the power of life-saving cancer treatments, a risk that doctors and patients can manage by being more selective about when and how these medications are prescribed.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.